万赛维疗效如何？

It is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients.

How effective is Vancevi?

Clinical studies of Vancevir in AIDS patients infected with CMV retinitis have shown that Vancevir and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to receive induction therapy with either Vancevir or intravenous ganciclovir. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups.

After induction therapy, both groups of patients in the study continued to receive maintenance therapy with 900 mg of Vancevir daily. The mean (median) time from randomization to progression of CMV retinitis was 226 (160) days and 219 (125) days in patients who received Vancevir or intravenous ganciclovir followed by maintenance therapy with Vancevir, respectively.

Oral ganciclovir achieves similar body exposure to ganciclovir at recommended doses of intravenous ganciclovir and is effective in the treatment of CMV retinitis. The area under the ganciclovir curve (AUC) correlates with the time to progression of CMV retinitis.

Prevention of CMV viral infection after transplantation: A double-blind, double-dummy, active-controlled clinical trial was conducted in high-risk patients (D+/R-) with CMV infection after heart, liver, and kidney transplantation. Patients started taking Vancevir (900 mg/time/day) or ciclovir (1000 mg tid) within 10 days after transplantation until 100 days after transplantation. CMV infection as judged by the Research Efficacy Committee includes CMV syndrome and tissue-invasive infection. The incidence of CMV infection within 6 months after transplantation was 12.1% in the Vancevir group (n=239) and 15.2% in the oral ganciclovir group (n=125). The majority of CMV infection cases occurred later in the vancevir group (after 100 days) than in the ganciclovir group after stopping preventive treatment. The incidence of acute rejection within 6 months after transplantation was 29.7% in the oral ganciclovir group and 36.0% in the oral ganciclovir group (n=125).